{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"BioBreakthroughs","title":"#21 - Simon Allen, Former CEO of Anebulo Pharmaceuticals","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/82c3fea3\"></iframe>","width":"100%","height":180,"duration":836,"description":"Join us on the latest episode! Our Guest: Simon Allen, Former CEO, Anebulo PharmaceuticalsWhat you'll get out of this episode:Journey from biochemistry to sell-side biotech business development.Current treatment landscape for ACI and the limitations therein.Introduction to ANEB-001, a promising antidote aimed at the CB1 receptor to counter cannabinoid overload.Impact of synthetic cannabinoids and the silent peril they pose.Upcoming milestones: Finalization of Phase 2 data and optimistic outlook towards FDA outcomes.*Since the recording of this episode Simon has moved onto new endeavors*To learn more about Anebulo Pharmaceuticals: https://www.anebulo.com/Our sponsors for this episode are:Sage Growth Partners https://sage-growth.com/","thumbnail_url":"https://img.transistorcdn.com/roxGfgcNItysBs3fg55SsdSx4l_Pbz86Ktm2KMDYkR4/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzQwNjg1LzE2ODE5/MzQxODQtYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}